Slide 1: Company presentation
Company presentation Per Norlén, CEO Strictly private and confidential BioEquity Europe Copenhagen, 10 May 2016
Slide 2: Alligator Bioscience in brief
Alligator Bioscience in brief KEY INVESTMENT HIGHLIGHTS HISTORY OF ASSET GROWTH Pioneering development of tumor-directed agonistic antibody based immuno-oncology drugs to out-license after POC ADC-1013 entering clinical phase I and first 2015 major out-licensing deal Fast growing and developing mark
Slide 3: Introduction to tumor-directed immuno-oncology
Introduction to tumor-directed immuno-oncology Metastases Immune activation Tumor SYSTEMIC IMMUNOTHERAPY TUMOR-DIRECTED IMMUNOTHERAPY Systemic administration of immunotherapeutic drugs, for instance by Selective activation of tumor-specific immune cells. This results in an intravenous injection, res
Slide 4: Fully integrated technology platforms
Fully integrated technology platforms ALLIGATOR-GOLD® FIND® ALLIGATOR-GOLD® is a fully human single-chain The FIND® technology is used to optimize antibody or library with large diversity protein characteristics D I V E R S I T Y > 1 0 10 OPTIMIZATION SUPERIOR COMPOUND Increased tumor retention
Slide 5: Extensive collaboration with distinguished immuno-oncologists
Extensive collaboration with distinguished immuno-oncologists Partners and major deliverables The Royal Stanford Navarra Lund Uppsala University of EU/TIMCC Institute of University University University University Manchester Technology Pre-clinical In-vivo In-vitro and in-vivo DC and T-cell
Slide 6: Rapid development within the field of immuno-oncology
Rapid development within the field of immuno-oncology Sales of existing immuno-oncology treatments Projected immuno-oncology market development US$ Million US$ Billion 2 634 30 566 21.5% 1 369 942 35.8% 960 706 360 1 126 42.8% 3 2011 2012 2013 2014 2015 2015 2023E Yervoy® Opdivo® Keytruda® Market po
Slide 7: Well-positioned drug development pipeline
Well-positioned drug development pipeline Development pipeline focusing on agonistic monospecific and bispecific antibodies targeting TNFR-SF EARLY LATE PROJECT MOLECULE TARGET RESEARCH RESEARCH PRE-CLINICAL PHASE I PHASE II STAGE STAGE ADC-1013 Monospecific CD40 ADC-1015 Bispecific OX40/CTLA-4 TNFR
Slide 8: ADC-1013: CD40 is a key immuno-oncology target
ADC-1013: CD40 is a key immuno-oncology target ADC-1013 Mode of Action Co-stimulating receptors ANTIGEN-PRESENTING CELL T CELL ANTIGEN-PRESENTING CELL T CELL PDL1 or PDL2 ? + ADC-1013 PDL1 or PDL2 PD1 – CD40 CD80 or CD86 CD28 + CD80 or CD86 CTLA4 – B7RP1 ICOS + B7-H3 ? – B7-H4 ? – T-cell HVEM BTLA –
Slide 9: ADC-1013: One of only four CD40 projects in clinical phase
ADC-1013: One of only four CD40 projects in clinical phase Selection of antibody based immuno-oncology drugs in clinical development Comments Company Drug Indication Phase Target Approx. 70 immuno-oncology drugs are currently in Roche (Genentech) atezolizumab NSCLC, bladder, renal, breast III PD-L
Slide 10: ADC-1013: Partnership with Janssen validating Alligator's model
ADC-1013: Partnership with Janssen validating Alligator’s model Partnership details for ADC-1013 Description of ongoing Phase I trial 40 patients with advanced solid tumors 5 clinical sites in the UK, DK and SE Description of agreement Royalty / Milestone potential Exclusive world-wide Up-fr
Slide 11: ADC-1015: Biological rationale for dual binding OX40 and CTLA-4
ADC-1015: Biological rationale for dual binding OX40 and CTLA-4 Design and optimization of the CTLA-4 binding part Anti-OX40 ADC-1015 Anti-CTLA-4 5 mutations were introduced Affinity increased 100-fold Mode of Action T-cell T-cell ACTIVATION OF ADC-1015 DEPLETION OF EFFECTOR T-CELLS REGULATORY T
Slide 12: Company strategy
Company strategy 1. Advance and broaden pipeline of agonistic tumor-directed Research project LEAD ID / OPTIMIZATION bispecific immune activating product candidates Research project ADC-1016 2. POC IN-VIVO Extend in-house product development to late-stage clinical phase before entering into strategi
Slide 13: Thank You!
Thank You! Strictly private and confidential